Basel, May 21, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the European launch of its Pyzchiva®* (ustekinumab) autoinjector.[1-2] This ...
The MarketWatch News Department was not involved in the creation of this content. -- SteQeyma(TM) 45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, ...
GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets ...
GlobalData on MSN
Teva and Alvotech launch ustekinumab biosimilar injection in US
Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...
Ustekinumab-stba is approved for multiple conditions, showing comparable efficacy and safety to Stelara in clinical trials. The biosimilar will be available in subcutaneous and intravenous forms, with ...
Launch strengthens Sandoz biosimilar leadership position in immunology and commitment to patient-centric innovation Basel, May 21, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and ...
19don MSN
Celltrion receives positive CHMP opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector
SteQeyma™ 45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback